Claudia Schoch - JoVE Visualize

Showing results (71-80 of 86) with videos related to

Pageof 9

Sort By:

Cancer|November 19, 2005

Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemiaGesine Bug, Markus Ritter, Barbara Wassmann, et al.

Oncogene|August 29, 2003

The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent mannerAnnika Elsässer, Michael Franzen, Alexander Kohlmann, et al.

Genes, Chromosomes & Cancer|July 18, 2006

Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion geneChristoph Walz, Claire Curtis, Susanne Schnittger, et al.

Blood|August 30, 2003

Expression analyses identify MLL as a prominent target of 11q23 amplification and support an etiologic role for MLL gain of function in myeloid malignanciesBruce Poppe, Jo Vandesompele, Claudia Schoch, et al.

Leukemia Research|January 17, 2002

Increased risk for therapy-associated hematologic malignancies in patients with carcinoma of the breast and combined homozygous gene deletions of glutathione transferases M1 and T1Detlef Haase, Claudia Binder, Jürgen Bünger, et al.

Proceedings of the National Academy of Sciences of the United States of America|January 1, 2005

Diagnostic tool for the identification of MLL rearrangements including unknown partner genesClaus Meyer, Bjoern Schneider, Martin Reichel, et al.

American Journal of Human Genetics|December 17, 2005

Diversity and functional consequences of germline and somatic PTPN11 mutations in human diseaseMarco Tartaglia, Simone Martinelli, Lorenzo Stella, et al.

Blood|October 25, 2003

Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinibBarbara Wassmann, Heike Pfeifer, Urban J Scheuring, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2006

Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemiaThomas Büchner, Wolfgang E Berdel, Claudia Schoch, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2003

6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative GroupThomas Büchner, Wolfgang Hiddemann, Wolfgang E Berdel, et al.

Pageof 9

Showing results (71-80 of 86) with videos related to

Sort By:

Pageof 9

Cancer|November 19, 2005

Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemiaGesine Bug, Markus Ritter, Barbara Wassmann, et al.

Oncogene|August 29, 2003

The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent mannerAnnika Elsässer, Michael Franzen, Alexander Kohlmann, et al.

Genes, Chromosomes & Cancer|July 18, 2006

Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion geneChristoph Walz, Claire Curtis, Susanne Schnittger, et al.

Blood|August 30, 2003

Expression analyses identify MLL as a prominent target of 11q23 amplification and support an etiologic role for MLL gain of function in myeloid malignanciesBruce Poppe, Jo Vandesompele, Claudia Schoch, et al.

Leukemia Research|January 17, 2002

Increased risk for therapy-associated hematologic malignancies in patients with carcinoma of the breast and combined homozygous gene deletions of glutathione transferases M1 and T1Detlef Haase, Claudia Binder, Jürgen Bünger, et al.

Proceedings of the National Academy of Sciences of the United States of America|January 1, 2005

Diagnostic tool for the identification of MLL rearrangements including unknown partner genesClaus Meyer, Bjoern Schneider, Martin Reichel, et al.

American Journal of Human Genetics|December 17, 2005

Diversity and functional consequences of germline and somatic PTPN11 mutations in human diseaseMarco Tartaglia, Simone Martinelli, Lorenzo Stella, et al.

Blood|October 25, 2003

Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinibBarbara Wassmann, Heike Pfeifer, Urban J Scheuring, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2006

Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemiaThomas Büchner, Wolfgang E Berdel, Claudia Schoch, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2003

6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative GroupThomas Büchner, Wolfgang Hiddemann, Wolfgang E Berdel, et al.

Pageof 9